2xfu › Citations

Potentiation of ligand binding through cooperative effects in monoamine oxidase B.

Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, Mattevi A
J Biol Chem 285 36849-56 (2010)
Related entries: 2xcg, 2xfn, 2xfo, 2xfp, 2xfq

Cited: 51 times
EuropePMC logo PMID: 20855894

Abstract

Crystallographic and biochemical studies have been employed to identify the binding site and mechanism for potentiation of imidazoline binding in human monoamine oxidase B (MAO B). 2-(2-Benzofuranyl)-2-imidazoline (2-BFI) inhibits recombinant human MAO B with a K(i) of 8.3 ± 0.6 μM, whereas tranylcypromine-inhibited MAO B binds 2-BFI with a K(d) of 9 ± 2 nM, representing an increase in binding energy Δ(ΔG) of -3.9 kcal/mol. Crystal structures show the imidazoline ligand bound in a site that is distinct from the substrate-binding cavity. Contributions to account for the increase in binding affinity upon tranylcypromine inhibition include a conformational change in the side chain of Gln(206) and a "closed conformation" of the side chain of Ile(199), forming a hydrophobic "sandwich" with the side chain of Ile(316) on each face of the benzofuran ring of 2-BFI. Data with the I199A mutant of human MAO B and failure to observe a similar binding potentiation with rat MAO B, where Ile(316) is replaced with a Val residue, support an allosteric mechanism where the increased binding affinity of 2-BFI results from a cooperative increase in H-bond strength through formation of a more hydrophobic milieu. These insights should prove valuable in the design of high affinity and specific reversible MAO B inhibitors.

Reviews - 2xfu mentioned but not cited (2)

  1. Inhibitors of Protein Methyltransferases and Demethylases. Kaniskan HÜ, Martini ML, Jin J. Chem Rev 118 989-1068 (2018)
  2. Quercetin and Related Chromenone Derivatives as Monoamine Oxidase Inhibitors: Targeting Neurological and Mental Disorders. Dhiman P, Malik N, Sobarzo-Sánchez E, Uriarte E, Khatkar A. Molecules 24 E418 (2019)

Articles - 2xfu mentioned but not cited (4)

  1. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, Mattevi A. J Biol Chem 285 36849-36856 (2010)
  2. Activity-dependent Regulation of Histone Lysine Demethylase KDM1A by a Putative Thiol/Disulfide Switch. Ricq EL, Hooker JM, Haggarty SJ. J Biol Chem 291 24756-24767 (2016)
  3. Parameters for Irreversible Inactivation of Monoamine Oxidase. Ramsay RR, Basile L, Maniquet A, Hagenow S, Pappalardo M, Saija MC, Bryant SD, Albreht A, Guccione S. Molecules 25 E5908 (2020)
  4. Protective effects of niacin following high fat rich diet: an in-vivo and in-silico study. Samad N, Manzoor N, Batool A, Noor A, Khaliq S, Aurangzeb S, Bhatti SA, Imran I. Sci Rep 13 21343 (2023)


Reviews citing this publication (13)

  1. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Finberg JP. Pharmacol Ther 143 133-152 (2014)
  2. Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. McCluskey SP, Plisson C, Rabiner EA, Howes O. Eur J Nucl Med Mol Imaging 47 451-489 (2020)
  3. Key Targets for Multi-Target Ligands Designed to Combat Neurodegeneration. Ramsay RR, Majekova M, Medina M, Valoti M. Front Neurosci 10 375 (2016)
  4. Structural insight into inhibitors of flavin adenine dinucleotide-dependent lysine demethylases. Niwa H, Umehara T. Epigenetics 12 340-352 (2017)
  5. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Carradori S, Secci D, Bolasco A, Chimenti P, D'Ascenzio M. Expert Opin Ther Pat 22 759-801 (2012)
  6. An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. Khan MN, Suzuki T, Miyata N. Med Res Rev 33 873-910 (2013)
  7. Imaging of Reactive Astrogliosis by Positron Emission Tomography. Harada R, Furumoto S, Kudo Y, Yanai K, Villemagne VL, Okamura N. Front Neurosci 16 807435 (2022)
  8. Monoamine oxidase A and B substrates: probing the pathway for drug development. Chajkowski-Scarry S, Rimoldi JM. Future Med Chem 6 697-717 (2014)
  9. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Duarte P, Cuadrado A, León R. Handb Exp Pharmacol 264 229-259 (2021)
  10. The structure of monoamine oxidases: past, present, and future. Iacovino LG, Magnani F, Binda C. J Neural Transm (Vienna) 125 1567-1579 (2018)
  11. Exploration of the Detailed Structure-Activity Relationships of Isatin and Their Isomers As Monoamine Oxidase Inhibitors. Kumar S, Nair AS, Abdelgawad MA, Mathew B. ACS Omega 7 16244-16259 (2022)
  12. On the practical aspects of characterising monoamine oxidase inhibition in vitro. Holt A. J Neural Transm (Vienna) 125 1685-1705 (2018)
  13. Structure-Based Design of Novel MAO-B Inhibitors: A Review. Mateev E, Georgieva M, Mateeva A, Zlatkov A, Ahmad S, Raza K, Azevedo V, Barh D. Molecules 28 4814 (2023)

Articles citing this publication (32)

  1. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. FEBS J 278 4860-4869 (2011)
  2. Empirical valence bond simulations of the hydride transfer step in the monoamine oxidase B catalyzed metabolism of dopamine. Repič M, Vianello R, Purg M, Duarte F, Bauer P, Kamerlin SC, Mavri J. Proteins 82 3347-3355 (2014)
  3. Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. Kumar A, Koistinen NA, Malarte ML, Nennesmo I, Ingelsson M, Ghetti B, Lemoine L, Nordberg A. Mol Psychiatry 26 5833-5847 (2021)
  4. What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase B Towards Histamine and N-Methylhistamine. Maršavelski A, Vianello R. Chemistry 23 2915-2925 (2017)
  5. Rationally engineered flavin-dependent oxidase reveals steric control of dioxygen reduction. Zafred D, Steiner B, Teufelberger AR, Hromic A, Karplus PA, Schofield CJ, Wallner S, Macheroux P. FEBS J 282 3060-3074 (2015)
  6. An improved approach to steady-state analysis of monoamine oxidases. Ramsay RR, Olivieri A, Holt A. J Neural Transm (Vienna) 118 1003-1019 (2011)
  7. Inhibition of MAO-A and stimulation of behavioural activities in mice by the inactive prodrug form of the anti-influenza agent oseltamivir. Hiasa M, Isoda Y, Kishimoto Y, Saitoh K, Kimura Y, Kanai M, Shibasaki M, Hatakeyama D, Kirino Y, Kuzuhara T. Br J Pharmacol 169 115-129 (2013)
  8. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases. Malcomson T, Yelekci K, Borrello MT, Ganesan A, Semina E, De Kimpe N, Mangelinckx S, Ramsay RR. FEBS J 282 3190-3198 (2015)
  9. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives. Sakane C, Okitsu T, Wada A, Sagami H, Shidoji Y. Biochem Biophys Res Commun 444 24-29 (2014)
  10. MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study, and docking calculations. Ferino G, Cadoni E, Matos MJ, Quezada E, Uriarte E, Santana L, Vilar S, Tatonetti NP, Yáñez M, Viña D, Picciau C, Serra S, Delogu G. ChemMedChem 8 956-966 (2013)
  11. Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. Pavlin M, Mavri J, Repič M, Vianello R. J Neural Transm (Vienna) 120 875-882 (2013)
  12. In silico target fishing for the potential targets and molecular mechanisms of baicalein as an antiparkinsonian agent: discovery of the protective effects on NMDA receptor-mediated neurotoxicity. Gao L, Fang JS, Bai XY, Zhou D, Wang YT, Liu AL, Du GH. Chem Biol Drug Des 81 675-687 (2013)
  13. Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives. Abdelhafez OM, Amin KM, Ali HI, Abdalla MM, Batran RZ. Neurochem Int 62 198-209 (2013)
  14. First Synthesis of Racemic Trans Propargylamino-Donepezil, a Pleiotrope Agent Able to Both Inhibit AChE and MAO-B, with Potential Interest against Alzheimer's Disease. Guieu B, Lecoutey C, Legay R, Davis A, Sopkova de Oliveira Santos J, Altomare CD, Catto M, Rochais C, Dallemagne P. Molecules 26 E80 (2020)
  15. ONIOM calculations on serotonin degradation by monoamine oxidase B: insight into the oxidation mechanism and covalent reversible inhibition. Cakir K, Erdem SS, Atalay VE. Org Biomol Chem 14 9239-9252 (2016)
  16. Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity. Dasgupta S, Mukherjee S, Mukhopadhyay BP, Banerjee A, Mishra DK. J Biomol Struct Dyn 36 1439-1462 (2018)
  17. Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study. Emanuela B, Minarini A, Tumiatti V, Milelli A, Lunelli M, Pegoraro M, Rizzoli V, Di Paolo ML. Amino Acids 42 913-928 (2012)
  18. Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B. Pandey P, Chaurasiya ND, Tekwani BL, Doerksen RJ. Biochem Pharmacol 155 82-91 (2018)
  19. 3D similarities between the binding sites of monoaminergic target proteins. Núñez-Vivanco G, Fierro A, Moya P, Iturriaga-Vásquez P, Reyes-Parada M. PLoS One 13 e0200637 (2018)
  20. Multiscale Modeling of Two-Photon Probes for Parkinson's Diagnostics Based on Monoamine Oxidase B Biomarker. Murugan NA, Zaleśny R. J Chem Inf Model 60 3854-3863 (2020)
  21. Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines. Wichitnithad W, O'Callaghan JP, Miller DB, Train BC, Callery PS. Bioorg Med Chem 19 7482-7492 (2011)
  22. Targeting imidazoline site on monoamine oxidase B through molecular docking simulations. Moraes FP, de Azevedo WF. J Mol Model 18 3877-3886 (2012)
  23. Why Monoamine Oxidase B Preferably Metabolizes N-Methylhistamine over Histamine: Evidence from the Multiscale Simulation of the Rate-Limiting Step. Maršavelski A, Mavri J, Vianello R, Stare J. Int J Mol Sci 23 1910 (2022)
  24. Computational methods for the discovery of mood disorder therapies. López-Vallejo F, Peppard TL, Medina-Franco JL, Martínez-Mayorga K. Expert Opin Drug Discov 6 1227-1245 (2011)
  25. Structure-Activity Relationship and In Silico Evaluation of cis- and trans-PCPA-Derived Inhibitors of LSD1 and LSD2. Niwa H, Watanabe C, Sato S, Harada T, Watanabe H, Tabusa R, Fukasawa S, Shiobara A, Hashimoto T, Ohno O, Nakamura K, Tsuganezawa K, Tanaka A, Shirouzu M, Honma T, Matsuno K, Umehara T. ACS Med Chem Lett 13 1485-1492 (2022)
  26. Why p-OMe- and p-Cl-β-Methylphenethylamines Display Distinct Activities upon MAO-B Binding. Fierro A, Edmondson DE, Celis-Barros C, Rebolledo-Fuentes M, Zapata-Torres G. PLoS One 11 e0154989 (2016)
  27. Performance of Force-Field- and Machine Learning-Based Scoring Functions in Ranking MAO-B Protein-Inhibitor Complexes in Relevance to Developing Parkinson's Therapeutics. Murugan NA, Muvva C, Jeyarajpandian C, Jeyakanthan J, Subramanian V. Int J Mol Sci 21 E7648 (2020)
  28. Binding mechanism of naringenin with monoamine oxidase - B enzyme: QM/MM and molecular dynamics perspective. Govindasamy H, Magudeeswaran S, Kandasamy S, Poomani K. Heliyon 7 e06684 (2021)
  29. MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study, and docking calculations. Delogu GL, Pintus F, Mayán L, Matos MJ, Vilar S, Munín J, Fontenla JA, Hripcsak G, Borges F, Viña D. Medchemcomm 8 1788-1796 (2017)
  30. Computational Chemistry and Molecular Modeling of Reversible MAO Inhibitors. Yelekçi K, Erdem SS. Methods Mol Biol 2558 221-252 (2023)
  31. Conventional Receptor Radioligand Binding Techniques Applied to the Study of Monoamine Oxidase. Holt A. Methods Mol Biol 2558 75-96 (2023)
  32. Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurogenerative disease treatment. Benny F, Oh JM, Kumar S, Abdelgawad MA, Ghoneim MM, Abdel-Bakky MS, Kukerti N, Jose J, Kim H, Mathew B. RSC Adv 13 35240-35250 (2023)


Related citations provided by authors (1)

  1. Potentiation of ligand binding through cooperative effects in monoamine oxidase B.. Bonivento D, Milczek EM, McDonald GR, Binda C, Holt A, Edmondson DE, Mattevi A J Biol Chem 285 36849-56 (2010)

Quick links